Structural and analytical reference
Compare BPC-157 and TB-500 by peptide sequence and chemical identity, including the distinction between a thymosin beta 4 fragment and the full-length peptide.
BPC-157 is a 15-residue peptide. TB-500 is a name that requires an exact structural definition: published analytical work identified an acetylated seven-residue thymosin beta 4 fragment, which must be distinguished from full-length thymosin beta 4.
Compare defined structures
| Attribute | BPC-157 | TB-500 fragment in the cited study |
|---|---|---|
| Sequence | GEPPPGKPADDAGLV | Ac-LKKTETQ |
| Residue count | 15 | 7 |
| Structural context | Distinct pentadecapeptide sequence | Thymosin beta 4 residues 17–23 with N-terminal acetylation |
| Key identity question | Does the tested material match the declared 15-residue structure? | Is the material this acetylated fragment or a different declared structure? |
Ac denotes an N-terminal acetyl group. Full-length thymosin beta 4 is a separate 43-residue peptide. The fragment identification in one study is not proof that every present-day product labeled TB-500 contains that same molecule.
Resolve the name before comparing the data
An alias can conceal the most important difference in a comparison. Ask for the complete sequence and terminal modifications rather than treating TB-500 as a self-sufficient chemical specification. A report naming full-length thymosin beta 4 should be interpreted against that structure, not against a seven-residue fragment.
The same principle applies to blends. A blend name does not replace component identities, declared composition or evidence that each component was evaluated. A single chromatographic percentage cannot silently become a separate purity result for each component.
Read the molecular profile correctly
Sequence length, acetylation and terminal groups change the expected molecular profile. The expected mass must therefore be calculated for the structure actually declared. A database entry for a fragment cannot validate a mass assignment for the full-length peptide.
- Match the sample label and lot identifier across the vial, report and product record.
- Check sequence, acetylation, terminal form and any declared counterion.
- Locate the expected and observed mass assignment, including ion charge.
- Review HPLC separation and any stated limitations on component identification.
Keep evidence attached to the right molecule
A paper studying full-length thymosin beta 4 is not direct evidence about a short fragment. Likewise, a paper on isolated BPC-157 does not establish the properties of a multi-component blend. Use the methods section to identify what the researchers actually tested before transferring a label from one context to another.
For SRL records, the batch-report archive provides a place to review available sample documentation. Those published records do not establish the lot that will be used for a future fulfillment; current lot identity should be confirmed separately.
Frequently asked questions
Is TB-500 always full-length thymosin beta 4?
The name is insufficient to decide. Request the exact declared sequence and compare it with the report.
Are BPC-157 and TB-500 interchangeable?
They are different molecular identities. A comparison should begin with their defined structures rather than a shared marketing category.
Can a purity percentage resolve a fragment-versus-full-length question?
No. That is an identity question requiring evidence matched to the declared structure.
Continue learning
Sources and scope
- Primary BPC-157 laboratory study, materials and methods. Supports the reported 15-residue sequence; biological outcomes are not summarized here.
- Esposito et al. (2012), structural identification of a TB-500 preparation. Identified Ac-LKKTETQ by HPLC and high-resolution MS.
This original SRL reference uses the linked scientific and labeling records for molecular or analytical context. It does not reproduce an experimental protocol or certify a supplier batch. Prepared October 2, 2026.
[…] BPC-157 research review discusses published laboratory context. The BPC-157 versus TB-500 comparison explains distinctions between substances. Neither authenticates a supplier […]